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Community-associated methicillin-resistant Staphy-
lococcus aureus (CA-MRSA) infections increased from
2000 to 2003 in hospitalized pediatric patients in Houston.
CA-MRSA was associated with greater illness than was
infection with methicillin-susceptible strains. Children with
CA-MRSA were younger and mostly African American. Of
MRSA isolates, 4.5% had the inducible macrolide-lin-
cosamide-streptogramin B phenotype.
C
ommunity-associated methicillin-resistant Staphy-
lococcus aureus (CA-MRSA) infection in children is
an increasing problem (1,2). However, we do not know
whether CA-MRSA and the historically more common
community-associated methicillin-susceptible Staphy-
lococcus aureus (CA-MSSA) have similar pathogenesis
and cause similar illness (3–5). In Houston, CA-MSSA
infections were reported initially to be more severe than
CA-MRSA infections (3), but further reports stated the
opposite (4,5). Our clinical impression was that CA-
MRSA infections were becoming more frequent and were
more severe than CA-MSSA infections. To test the validi-
ty of our clinical impression, we performed a retrospective
chart review of hospitalized pediatric patients with S.
aureus infections during a 3-year interval. We determined
prevalence, clinical characteristics, susceptibility patterns,
and empiric antimicrobial regimens for CA-MRSA and
CA-MSSA.
The Study
We performed a retrospective chart review of pediatric
patients (<18 years of age) who were admitted to
Memorial Hermann Children’s Hospital, Houston, Texas,
in a 36-month period (July 2000 to June 2001 and January
2002 to December 2003; we excluded the second semester
of 2001 from the analysis because the hospital and the
microbiology laboratory were temporarily closed in July
2001). Alaboratory report of isolation of S. aureus from an
inpatient qualified the person as a candidate. From these
candidates, patients with underlying illness predisposing to
frequent hospitalization (immunodeficiency, cystic fibro-
sis, chronic renal failure, malignancy) and patients who
had been previously hospitalized or underwent surgery
within 3 months before S. aureus isolation were excluded.
Patients from the neonatal intensive care unit and patients
with mixed cultures were also excluded. For the remaining
patients (N = 239), community-associated S. aureus was
defined as the isolation of S. aureus from a culture
obtained within 72 h of admission. Antimicrobial resist-
ance testing was performed by broth microdilution MIC
method by the Clinical Microbiology Laboratory (Pasco,
Becton Dickinson, Sparks, MD, USA).
Clinical and Laboratory Standards Institute (CLSI)
(formerly NCCLS) standards and guidelines were used to
interpret MICs for clindamycin, erythromycin, gentamicin,
linezolid, minocycline, oxacillin, fluoroquinolones
(ciprofloxacin, levofloxacin, gatifloxacin), rifampin,
trimethoprim/sulfamethoxazole (TMP/SMX), and van-
comycin. For MRSA isolates that were erythromycin
resistant and clindamycin susceptible, inducible
macrolide-lincosamide-streptogramin B (MLSB) resist-
ance was determined by the disk diffusion method (6).
Demographic and clinical characteristics between CA-
MRSA and CA-MSSA were compared by Student t test or
Wilcoxon signed rank for continuous variables and chi-
square/Yates correction or Fischer exact test for categori-
cal variables.
From 2000 to 2003, CA-MRSA accounted for 67%
(159/239) of community-associated S. aureus infections in
hospitalized pediatric patients (56% in 2000–2001, 57% in
2002, and 78% in 2003, p<0.01 for trend). Patients with
CA-MRSA infections were significantly younger and
more likely to be African American than patients with CA-
MSSA infections, which is consistent with results from a
previous study (3). Patients with CA-MRSA tended to
have longer duration of bacteremia and significantly more
surgical interventions (incision, aspiration, drainage, or
débridement) (Table 1). Both groups had similar duration
of hospitalization, intensive care unit treatment, proportion
of positive blood culture, peripheral leukocyte counts, and
erythrocyte sedimentation rates at admission (data not
shown).
CA-MRSA infections were seen more frequently with
abscesses and complicated pneumonias (Table 2). The
locations of the abscesses were similar in both groups; the
most common sites were the extremities, gluteal, and
perirectal areas. Among deep abscesses, 2 mediastinal and
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USA1 retropharyngeal abscess were CA-MRSA, and 1
retropharyngeal abscess was CA-MSSA. Among patients
with pneumonia, 12 of 17 CA-MRSAwere complicated (9
empyemas and 3 pneumatocele/pneumothorax) versus 2 of
13 CA-MSSA (1 empyema and 1 pneumatocele). Only 2
patients had a documented viral pneumonia before the S.
aureus pneumonia. Among patients with osteoarticular
infections, both groups had similar involvement and com-
plications. In the CA-MRSA group (10 patients) were 7
osteomyelitis, 5 septic arthritis, 1 myositis, 1 deep venous
thrombosis, and 4 bacteremia cases. In the CA-MSSA
group (8 patients) were 8 osteomyelitis, 2 septic arthritis, 3
myositis, 1 deep venous thrombosis, and 4 bacteremia
cases.
CA-MRSA isolates were more likely to be resistant to
erythromycin (92% vs. 45%, p<0.01) and fluoro-
quinolones (16% vs. 4%, p<0.01). Resistance to clin-
damycin was 5% in both groups. All CA-MRSA and
CA-MSSA isolates were susceptible to gentamicin, line-
zolid, minocycline, rifampin, TMP/SMX, and van-
comycin. Atotal of 3 (4.5%) of 66 CA-MRSAisolates had
the inducible MLSB-resistant phenotype. Clindamycin
was the most commonly used antimicrobial drug. It was
the initial empiric treatment for 60% of both CA-MRSA
and CA-MSSA infections when used alone or in combina-
tion with other antimicrobial drugs. The use of clin-
damycin increased over time (32% in 2001, 54% in 2002,
and 66% in 2003, p<0.001). The empiric use of van-
comycin was more frequent in the CA-MRSAgroup (25%
vs. 12%, p<0.05) but did not increase over time. Nafcillin
use was similar in both groups (8% vs. 11%). For 16% of
the CA-MRSAcases, empiric therapy was with an agent to
which the infecting isolate was later found not to be sus-
ceptible in vitro, regardless of the clinical outcome. 
Conclusions
CA-MRSA is seen with increasing frequency in
Houston; it is a more severe infection with more frequent
serious complications, compared to CA-MSSA. The
increasing frequency of severe S. aureus infection requires
reassessing regimens of empiric therapy delivered on
admission and added emphasis to timely and appropriate
acquisition of specimens for culture.
Since 2000, rates of pediatric CA-MRSA in our hospi-
tal have increased from 56% to 78%; these infections are
associated with greater illness, especially empyema and
necrotizing pneumonia, compared to CA-MSSA infec-
tions. A similar increase in MRSA frequency and severity
has been reported from another pediatric hospital in
Houston (4,5). Of all CA-MRSA isolates reported from
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characteristics and rates across institutions support the
hypothesis that CA-MRSA in Houston are related, but
molecular genetic analysis of our strains would be neces-
sary to confirm this hypothesis. 
Emerging CA-MRSA is a global problem (1,2). For
some regions, direct evidence shows an association
between clonality of CA-MRSA and severity (5,8–10).
This association seems to be related to specific virulence
factors, such as the Panton-Valentine leukocidin, among
others (10,11) . In a recent study from Houston, strains car-
rying the pvl gene were associated with severe staphylo-
coccal sepsis in adolescents (5) and with CA-MRSA
musculoskeletal infection in children (8). The presence of
the pvl gene may be related to an increased likelihood of
complications in children with S. aureus infections. The
present study lacks molecular genetic analysis of the
strains to support this hypothesis.
Treatment of MRSA infections is challenging. Empiric
treatment usually includes the use of clindamycin or van-
comycin (2,4). MRSAstrains that are clindamycin-suscep-
tible but erythromycin-resistant may have the in vitro
inducible MLSB-resistance phenotype with potential for
treatment failure (12–14). Rates of inducible MLSB resist-
ance among pediatric MRSA isolates vary widely. Our
results are similar to those from previous studies from
Houston (2%–8% inducible MLSB resistance) (3,4) and
different from reports from cities such as Baltimore (43%)
(13) and Chicago (94%) (12). Awareness of local resist-
ance patterns is required to select adequate empiric thera-
py. Trends in clindamycin use could indicate physician
awareness of MRSA resistance patterns. The increasing
penetration of CA-MRSA in the community requires dis-
seminating information to primary care providers about
the potential severity of this infection, methods for rapid
and accurate diagnosis, and need to rapidly implement
appropriate empiric and definitive treatment regimens.
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